Recurrent Hodgkin's lymphoma is still a vexing clinical problem. Although initially responsive to chemotherapy, recurrences can be insensitive to standard therapies, particularly after high intensity treatment regimens. Hodgkin's lymphoma frequently manifests with multifactorial microenvironmental and immunological changes and molecular therapy capable of addressing these changes might be beneficial. As such, an epigenetic therapy, with its multifaceted modes of action, would seem a rational candidate...